Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Official Title
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Quick Facts
Study Start:2022-03-09
Study Completion:2037-07-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
Mayo Clinic Cancer Center-Scottsdale
Phoenix, Arizona, 85054
United States
City of Hope
Duarte, California, 91010
United States
University of California San Francisco
San Francisco, California, 94143
United States
Stanford University Medical Center
Stanford, California, 94305-5623
United States
Emory University
Atlanta, Georgia, 30322
United States
Northwestern University
Chicago, Illinois, 60611
United States
University of Chicago
Chicago, Illinois, 60637
United States
Indiana University
Indianapolis, Indiana, 46202
United States
Kansas University Medical Center
Westwood, Kansas, 66205
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Massachusetts General Hospital
Boston, Massachusetts, 02215
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
United States
Mayo Clinic Rochester
Rochester, Minnesota, 55902
United States
Washington University School Of Medicine
Saint Louis, Missouri, 63110
United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
United States
Montefiore Medical Center
Bronx, New York, 10467
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263
United States
Mount Sinai Medical Center
New York, New York, 10029
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Levine Cancer Institute
Charlotte, North Carolina, 28204
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232
United States
Sarah Cannon Research Institute
Nashville, Tennessee, 37203
United States
MD Anderson Cancer Center
Houston, Texas, 77030
United States
Froedtert Memorial
Milwaukee, Wisconsin, 53226
United States
Collaborators and Investigators
Sponsor: Janssen Research & Development, LLC
- Janssen Research & Development, LLC Clinical Trial, STUDY_DIRECTOR, Janssen Research & Development, LLC
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2022-03-09
Study Completion Date2037-07-29
Study Record Updates
Study Start Date2022-03-09
Study Completion Date2037-07-29
Terms related to this study
Additional Relevant MeSH Terms